Business & Regulation

Thoughts on the US National Institutes of Health and its role in funding research for non-opioid therapeutics.

FDA letter sent to Edenbridge Pharmaceuticals demonstrates the challenges of getting pharma advertising right.

Neal Baer, editor of a collection of essays on CRISPR, says we must not overlook the dark side of the technology.

The role of digital technologies in optimizing traceability in pharmaceutical supply chains.

US Senator Elizabeth Warren calls for a federal investigation into GSK and its discontinuation of Flovent HFA

We take a deep dive into key industry trends off the back of Clarivate’s Drugs to Watch 2025 report

In part 2 of our roundtable discussion, thought leaders discuss what Trump could do for drug pricing and whether change is to be feared or embraced.

We speak with Clarivate about their report listing eleven key drugs to watch in 2025.

Biden pushed drug pricing reforms, whereas Trump is known for deregulation. What does this mean for pharma?

Radiopharmaceuticals are a promising approach to cancer, but some countries are lagging behind. A collaboration hopes to change that.